Yahoo
    NasdaqGS - Nasdaq Real Time Price USD

    PepGen Inc. (PEPG)

    2.3600 -0.0500 (-2.07%)
    At close: October 30 at 4:00:00 PM EDT
    2.4100 +0.0500 (+2.12%)
    After hours: October 30 at 7:49:32 PM EDT
    Trade PepGen on Coinbase
    Chart Range Bar
    Advanced Chart
    AlphaSpace Chart
    Loading chart for PEPG
    • Previous Close 2.4100
    • Open 2.4000
    • Bid 1.7200 x 200
    • Ask 2.8500 x 200
    • Day's Range 2.2200 - 2.4050
    • 52 Week Range 1.3100 - 7.8000
    • Volume 1,129,063
    • Avg. Volume 951,282
    • Market Cap (intraday) 163.239M
    • Beta (5Y Monthly) 2.01
    • PE Ratio (TTM) --
    • EPS (TTM) -1.0100
    • Earnings Date (est.) Nov 11, 2026
    • Forward Dividend & Yield -- (0.00%)
    • 1y Target Est 10.19
    • Zacks Rating Neutral

    PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

    www.pepgen.com

    57

    Full Time Employees

    December 31

    Fiscal Year Ends

    Healthcare

    Sector

    Biotechnology

    Industry

    More about PepGen Inc.

    Recent News

    View More
    View More

    Performance Overview

    Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

    YTD Return

    PEPG
    63.75%
    S&P 500 (^GSPC)
    10.73%

    1-Year Return

    PEPG
    47.90%
    S&P 500 (^GSPC)
    11.11%

    3-Year Return

    PEPG
    57.93%
    S&P 500 (^GSPC)
    81.91%

    5-Year Return

    PEPG
    84.87%
    S&P 500 (^GSPC)
    64.59%

    Earnings Trends

    View More

    Earnings Per Share

    GAAP
    Normalized
    GAAP
    Normalized

    Revenue vs. Earnings

    Annual
    Quarterly
    Annual
    Quarterly
    Q2 FY26
    Revenue --
    Earnings -17.81M
    Profit Margin 0.00%

    Q2

    FY25

    Q3

    FY25

    Q4

    FY25

    Q2

    FY26

    -20M
    -15M
    -10M
    -5M
    0
    0.0%
    View More

    Analyst Insights

    View More

    Analyst Price Targets

    2.50
    10.19 Average
    2.3600 Current
    20.00 High

    Analyst Recommendations

    • Strong Buy
    • Buy
    • Hold
    • Underperform
    • Sell

    Latest Rating

    Date 9/9/2026
    Analyst HC Wainwright & Co.
    Rating Action Reiterates
    Rating Buy
    Price Action Maintains
    Price Target 20 -> 20
    View More

    Statistics

    View More

    Valuation Measures

    Annual

    • Market Cap

    • Enterprise Value

    • Trailing P/E

    • Forward P/E

    • PEG Ratio (current)

    • Price/Sales (ttm)

    • Price/Book (mrq)

    • Enterprise Value/Revenue

    • Enterprise Value/EBITDA

    Financial Highlights

    Profitability and Income Statement

    • Profit Margin

      0.00%

    • Return on Assets (ttm)

      -39.12%

    • Return on Equity (ttm)

      -75.45%

    • Revenue (ttm)

      --

    • Net Income Avi to Common (ttm)

      -71.94M

    • Diluted EPS (ttm)

      -1.0100

    Balance Sheet and Cash Flow

    • Total Cash (mrq)

      117.24M

    • Total Debt/Equity (mrq)

      13.46%

    • Levered Free Cash Flow (ttm)

      -43.25M

    View More

    Company Insights

    Research Reports

    View More
    View More

    People Also Watch

    GLUE Monte Rosa Therapeutics, Inc.
    10.76 -1.01%
    MLYS Mineralys Therapeutics, Inc.
    18.18 -14.41%
    ACRV Acrivon Therapeutics, Inc.
    1.6600 -5.68%
    TYRA Tyra Biosciences, Inc.
    21.07 -1.91%
    EWTX Edgewise Therapeutics, Inc.
    38.90 -0.03%
    Mobilize your Website
    View Site in Mobile | Classic
    Share by: